Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Varicella zoster vaccine (recombinant)

    go.drugbank.com/drugs/DB13924
    ApprovedInvestigational

    The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). … Herpes zoster, also known as shingles, is caused by a reactivation of Varicella Zoster Virus (VZV), the virus that commonly causes Chickenpox in childhood.

    Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein E
  2. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line … therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, 5, and 6 [L852].

  3. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. … [A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®.

    Products: Penta-buspirone
  4. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    Imdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. … [L23539] This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.

  5. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  6. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

  7. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    Nonivamide is a flavoring ingredient. Nonivamide is an organic compound and a capsaicinoid. It is an amide of pelargonic acid and _vanillylamine_. … It is naturally found in chili peppers but manufactured to produce a synthetic form for various pharmacologic preparations [L2641].

    Synonyms: N-Vanillylnonamide, N-Nonanoyl vanillylamide
  8. Drug

    Starch, corn

    go.drugbank.com/drugs/DB11599
    ApprovedInvestigationalNutraceutical

    Corn starch may be added in some food products as a thickening agent or anti-caking agent, and is sometimes found in topical drugs as a skin protectant. … Starch is any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may … [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163]

  10. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque

    Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled pen